Photocure ASA ( (PHCUF) ) has released its Q4 earnings. Here is a breakdown of the information Photocure ASA presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Photocure ASA, a company specializing in innovative solutions for bladder cancer treatment, reported its financial results for the fourth quarter and full year 2024, highlighting significant growth in key regions. The company achieved a 13% increase in Hexvix/Cysview revenue during Q4 2024, reaching a record high. North America saw a 20% revenue growth, primarily driven by increased unit sales and pricing, while Europe reported a 9% rise. Photocure’s commercial EBITDA grew by 98% year-over-year, reflecting the company’s operational efficiency and market expansion strategies. Despite these achievements, Photocure faced challenges with a decline in flexible BLC unit sales. Looking ahead, the company anticipates continued revenue growth between 7% and 11% in 2025, with ongoing investments in commercial expansion and product development expected to drive future success.
